Physician profile
Suneel Kumar
NPI 1811710932
$1,455.61
in general payments reported to CMS, 2019-2025
20 companies · $1,313 in 2025
The $1,313 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $143 · 2025: $1,313.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,245 · Travel and Lodging: $211.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,244.63 |
| Travel and Lodging | $210.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $228.23 | 2024-2025 | Crexont |
| Medtronic, INC. | $210.98 | 2025 | Percept PC Brainsense |
| Biogen, INC. | $146.26 | 2025 | Skyclarys, Leqembi |
| Neurocrine Biosciences, INC. | $128.42 | 2025 | |
| Acadia Pharmaceuticals INC | $103.25 | 2024-2025 | Nuplazid |
| Alexion Pharmaceuticals, INC. | $100.51 | 2025 | Ultomiris |
| Merz Pharmaceuticals, LLC | $78.84 | 2025 | Inbrija, Xeomin |
| Ucb, INC. | $75.64 | 2025 | Rystiggo, Zilbrysq |
| Averitas Pharma INC. | $58.80 | 2025 | Qutenza |
| Eisai INC. | $54.62 | 2025 | |
| Tanabe Pharma America, INC. | $45.69 | 2025 | Radicava |
| Lilly USA, LLC | $32.93 | 2025 | Kisunla |
| Lundbeck LLC | $32.43 | 2024 | Vyepti |
| Argenx US, INC. | $28.10 | 2024 | Vyvgart Hytrulo |
| Abbvie INC. | $25.71 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $25.43 | 2025 | |
| Kyowa Kirin, INC. | $24.48 | 2024 | Nourianz |
| Heartflow, INC. | $21.09 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.44 | 2025 | Hyqvia |
| Chiesi USA, INC. | $13.76 | 2025 | Cleviprex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suneel Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.